Evidence map›Paper›PMID 38539546›Full record

ArticleCancers2024

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment.

Michele Moreau, Lensa S Keno, Debarghya China, Serena Mao, Shahinur Acter, Gnagna Sy, Hamed Hooshangnejad, Kwok Fan Chow, Erno Sajo, Jacques Walker and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Michele MoreauDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0002-6881-6300
Lensa S KenoDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Debarghya ChinaDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0001-9053-8119
Serena MaoDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Shahinur ActerDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0001-7908-3870
Gnagna SyDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0001-7610-8788
Hamed HooshangnejadDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0002-1953-0568
Kwok Fan ChowDepartment of Chemistry and Department of Physics (Medical Physics), University of Massachusetts Lowell, Lowell, MA 01854, USA.
Erno SajoDepartment of Chemistry and Department of Physics (Medical Physics), University of Massachusetts Lowell, Lowell, MA 01854, USA.ORCID 0000-0001-6802-0014
Jacques WalkerNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Philmo OhNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Eric BroylesNanocan Therapeutics Corporation, Princeton, NJ 08540, USA.
Kai DingDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.ORCID 0000-0002-8202-0173
Akila ViswanathanDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Wilfred NgwaDepartment of Radiation Oncology and Molecular Radiation Sciences, Department of Biomedical Engineering, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
Johns Hopkins Hospital · USUniversity of Massachusetts Lowell · USUniversity of Scranton · US

Funding

Biomaterial Drones for Image-Guided Drug Delivery during radiotherapyR01CA239042 · NCI · JOHNS HOPKINS UNIVERSITY · PI NGWA, WILFRED · 2019 to 2023
$3.2M
Spacer Enabled Robust Radiation Therapy (SERRT)R37CA229417 · NCI · JOHNS HOPKINS UNIVERSITY · PI DING, KAI · 2018 to 2021
$1.5M
Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer TreatmentR41CA268623 · NCI · NANOCAN THERAPEUTICS CORPORATION · PI NGWA, WILFRED, SHILLING, ADAM · 2022 to 2022
$400k
NCI NIH HHS R01 CA239042NCI NIH HHS R37 CA229417NCI NIH HHS R41 CA268623NIH HHS award number R41CA268623 and R01CA239042
6 · The paper itself

Abstract

Globally, cervical cancer is the fourth leading cancer among women and is dominant in resource-poor settings in its occurrence and mortality. This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) imaging visibility were also evaluated in human cadavers. A pharmacodynamics study was also conducted to assess the safety of LIFE Biomaterial in healthy C57BL6 female mice. Results showed that LIFE Biomaterial could provide both CT and MR imaging contrast over time. Inhibition in tumor growth and prolonged significant survival (*

Indexed as

anti-CD40cervical cancerimage-guided radiotherapyliquid fiducialssmart radiotherapy biomaterialstoxicities

Identifiers

PMID38539546
PMCPMC10969426
OpenAlexW4393005510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.